-
Mashup Score: 18Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type - PubMed - 7 day(s) ago
Implications for cancer survivors are to raise awareness of aspects of long-term and late effects on QoL in TC survivors; offer supportive care, such as psycho-oncological support or lifestyle modification, if a deterioration in QoL is noticed; and avoid toxic treatment without compromising a cure w …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type - PubMed - 7 day(s) ago
Implications for cancer survivors are to raise awareness of aspects of long-term and late effects on QoL in TC survivors; offer supportive care, such as psycho-oncological support or lifestyle modification, if a deterioration in QoL is noticed; and avoid toxic treatment without compromising a cure w …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Testicular Cancer Awareness Foundation Keeps the Ball Rolling with In-Person Conference - American Urological Association - 7 day(s) ago
After 3 years of virtual conferences as a result of the global coronavirus pandemic, October 2023 marked the Testicular Cancer Awareness Foundation’s (TCAF) fifth in-person Testicular Cancer Conference (Figures 1-11). Fennec Pharmaceuticals was the title sponsor for the conference hosted at the epicenter of testicular cancer research and treatment, Indiana University. Dr Clint Cary, associate professor of urology at Indiana University and international authority on germ cell tumors, provided organizational oversight.
Source: auanews.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15
ed therapy, including surgical interventions, chemotherapy regimens, and radiation therapy. The effectiveness of these treatments varies depending on the site of metastasis, with various approaches improving survival rates and quality of life for patients. We divide our review in an organ-specific manner and focus on chemotherapeutic, surgical, and radiation therapy approaches pertaining to each site of metastasis. Summary Our review suggests the pressing need for continued research to refine and personalize treatment strategies. These efforts are important for enhancing clinical practice, ultimately leading to better outcomes for patients with metastatic testicular cancer….
Source: journals.lww.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19
To evaluate the oncological outcomes and safety of primary retroperitoneal lymph node dissection (RPLND) in patients with clinical stage (CS) II seminomatous testicular germ cell tumor (TGCT). A literature search using PubMed, Scopus, and Cochrane Library was conducted on July 2023 to identify relev …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31MicroRNAs in Testicular Germ Cell Tumors: The Teratoma Challenge - 2 month(s) ago
Testicular germ cell tumors (TGCTs) are relatively common in young men, making accurate diagnosis and prognosis assessment essential. MicroRNAs (miRNAs), including microRNA-371a-3p (miR-371a-3p), have shown promise as biomarkers for TGCTs. This review discusses the recent advancements in the use of miRNA biomarkers in TGCTs, with a focus on the challenges surrounding the noninvasive detection of teratomas. Circulating miR-371a-3p, which is expressed in undifferentiated TGCTs but not in teratomas, is a promising biomarker for TGCTs. Its detection in serum, plasma, and, potentially, cystic fluid could be useful for TGCT diagnosis, surveillance, and monitoring of therapeutic response. Other miRNAs, such as miR-375-3p and miR-375-5p, have been investigated to differentiate between TGCT subtypes (teratoma, necrosis/fibrosis, and viable tumors), which can aid in treatment decisions. However, a reliable marker for teratoma has yet to be identified. The clinical applications of miRNA biomarker
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14Lifestyle Medicine in Prostate Cancer | BackTable Urology Podcast - 2 month(s) ago
Listen to the BackTable Urology Podcast on Lifestyle Medicine in Prostate Cancer with Dr. Stacy Loeb. Visit BackTable.com.
Source: www.backtable.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
To evaluate the oncological outcomes and safety of primary retroperitoneal lymph node dissection (RPLND) in patients with clinical stage (CS) II semin…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
To evaluate the oncological outcomes and safety of primary retroperitoneal lymph node dissection (RPLND) in patients with clinical stage (CS) II semin…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Propensity-matched Analysis of Open Versus Robotic Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II Testicular Cancer - PubMed - 3 month(s) ago
To the best of our knowledge, this is the first study to compare open and robotic retroperitoneal lymph node dissection (R-RPLND) using a propensity score-matched system. We encourage the discussion and inclusion of primary R-RPLND into the standard of care algorithm for patients with de novo clinic …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
Long-term QOL of #GCT patients according to adj treatment https://t.co/DqyjPTKV8S Crucial data informing impact of RPLND, chemo, XRT in CSI and >CSI GCT patients. Surveillance preferred option, but this can guide discussion! @siadaneshmand @uroegg @drphil_urology @nirmishsingla